Abstract
After invasive ductal carcinoma, invasive lobular carcinoma (ILC) is the most frequent breast cancer and accounts for nearly 15% of all breast cancers (BC). Doxorubicin (DXR) is a very effective chemotherapeutic drug utilized to treat BC but induces drug resistance and severe side effects. Recently, liposomes have gained popularity as effective tumor microenvironment (TME) modulatory anticancer agents for various malignancies, including BC. This study propose a liposomal-DXR combination to produce an immune-responsive regulatory effect on competing endogenous RNAs (ceRNAs) through alteration in TME and investigate the immunological and anticancer impact of liposomal-DXR combination via regulation of ceRNAs and immune regulatory cytokines at BC cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
